Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) EBIT Margin (2024 - 2025)

Historic EBIT Margin for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Q3 2025 value amounting to 258.26%.

  • Monte Rosa Therapeutics' EBIT Margin rose 295700.0% to 258.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.69%, marking a year-over-year increase of 8659800.0%. This contributed to the annual value of 107.26% for FY2024, which is N/A changed from last year.
  • Per Monte Rosa Therapeutics' latest filing, its EBIT Margin stood at 258.26% for Q3 2025, which was up 295700.0% from 67.06% recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year EBIT Margin high stood at 51.85% for Q1 2025, and its period low was 3284.49% during Q1 2024.